Laboratory:Hachioji

Laboratory:Hachioji
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
---|---|---|---|---|---|---|---|
Anti-nuclear antibody (ANA)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
FA Fluorescent antibody method (FA) |
< 40 (x) |
Anti-DNA antibody, RIA
|
serum
0.2 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
RIA ammonium sulfate precipitation method Radio immunoassay (RIA) |
≦ 6.0 (IU/mL) |
Anti-ss DNA antibody, IgG
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
≦ 25 (AU/mL) |
Anti-ss DNA antibody, IgM
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-8 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 17 (U/mL) |
Anti-ds DNA antibody, IgG
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
≦ 12 (IU/mL) |
Anti-ds DNA antibody, IgM
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-8 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 6 (U/mL) |
Anti-Sm antibody
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
3-5 |
Ouchterlony Ouchterlony method(Ouchterlony double immunodiffusion) |
Negative (x) |
Anti-Sm antibody, CLEIA
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 10.0 (U/mL) |
Anti-RNP antibody
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
3-5 |
Ouchterlony Ouchterlony method(Ouchterlony double immunodiffusion) |
Negative (x) |
Anti-RNP antibody, CLEIA
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 10.0 (U/mL) |
Anti-SS-A/Ro antibody
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
3-5 |
Ouchterlony Ouchterlony method(Ouchterlony double immunodiffusion) |
Negative (x) |
Anti-SS-A/Ro antibody, CLEIA
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 10.0 (U/mL) |
Anti-SS-B/La antibody
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
3-5 |
Ouchterlony Ouchterlony method(Ouchterlony double immunodiffusion) |
Negative (x) |
Anti-SS-B/La antibody, CLEIA
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 10.0 (U/mL) |
Anti-Scl-70 antibody
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
3-5 |
Ouchterlony Ouchterlony method(Ouchterlony double immunodiffusion) |
Negative (x) |
Anti-Scl-70 antibody, CLEIA
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 10.0 (U/mL) |
Anti-RNA polymerase III antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 28 See the following criteria. |
Anti-centromere antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 10.0 See the following criteria. |
Anti-Jo-1 antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
3-5 |
Ouchterlony Ouchterlony method(Ouchterlony double immunodiffusion) |
Negative (x) |
Anti-Jo-1 antibody, CLEIA
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 10.0 (U/mL) |
Anti-ARS antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
Negative < 25.0 |
Rheumatoid factor (RF), quantitative
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 | Latex aggulutination immunoassay |
≦ 15 (IU/mL) |
Rheumatoid factor, IgG
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 2.00 |
Anti-galactose deficient IgG antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ECLIA Electro chemiluminescence immunoassay (ECLIA) |
< 6.0 (AU/mL) |
Anti-cyclic citrullinated peptide (CCP) antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 4.5 (U/mL) |
Anti-mitochondrial antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
FA Fluorescent antibody method (FA) |
Negative (< 20) (x) |
Anti-mitochondrial M2 antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 7.0 |
Anti-smooth muscle antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
FA Fluorescent antibody method (FA) |
Negative (< 40) (x) |
Anti-parietal cell antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
FA Fluorescent antibody method (FA) |
Negative (< 10) (x) |
Anti-intrinsic factor antibody
|
serum
0.8 |
S09 ↓ A00 |
![]() |
![]() |
2-6 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
(-) |
Fecal calprotectin
|
stool
|
F30 |
![]() (28 days) |
3-7 |
FEIA Fluorescence enzyme immunoassay (FEIA) |
≦ 50.0 (mg/kg) |
|
Fecal calprotectin
|
stool
1g |
F00 |
![]() |
![]() |
5-9 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
<94.0 (μg/g) |
Leucine-rich alpha 2 glycoprotein (LRG)
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-4 | Latex agglutination immunoassay |
< 16.0 (cutoff) (μg/mL) |
Anti-melanoma differentiation associated gene 5 (MDA5) antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
<32 Negative |
Anti-Mi-2 antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
<53 Negative |
Anti-transcriptional intermediary factor 1-γ(TIF1- γ) antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
<32 Negative |
Anti-thyroid peroxidase antibody (Anti- TPO antibody), CLEIA
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
<3.3 (IU/mL) |
Anti-thyroglobulin antibody, CLEIA
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
<19.3 (IU/mL) |
Thyroid stimulating antibody (TSAb)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 | Bioassay |
<110 (%) |
|
serum
0.2 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Radioreceptorassay (RRA) Radioreceptor assay (RRA) |
≦ 15 (%) |
TSH receptor antibody, quantitative
|
serum
0.4 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Radioreceptorassay (RRA) Radioreceptor assay (RRA) |
< 1.0 (IU/L) |
TSH receptor antibody, CLEIA
|
serum
0.8 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
<2.0 (IU/L) |
Anti-GAD antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 5.0 (U/mL) |
Anti-IA-2 antibody
|
serum
0.6 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
3-9 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 0.6 (U/mL) |
Zinc transporter 8 (ZnT8) antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
Please contact us in advance. |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 15.0 (U/mL) |
Insulin antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
3-7 |
RIA Radio immunoassay (RIA) |
< 0.4 (U/mL) |
Anti-acethylcholine receptor antibody(anti-AChR antibody)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
3-7 |
RIA Radio immunoassay (RIA) |
≦ 0.2 (nmol/L) |
Muscle-specific receptor tyrosine kinase antibody (anti-MuSK antibody)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
3-9 |
RIA Radio immunoassay (RIA) |
< 0.02 (nmol/L) |
Anti-P/Q-type voltage-gated calcium channels (Anti-P/Q VGCCs antibody)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-8 |
RIA Radio immunoassay (RIA) |
<30.0 (pmol/L) |
Anti-desmoglein 1 antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 20.0 (U/mL) |
Anti-desmoglein 3 antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 20.0 (U/mL) |
BP180 antibody (serum anti-BP180NC16a antibody)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 9.0 (U/mL) |
Anti-glomerular basement membrane antibody (anti-GBM antibody)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 3.0 (U/mL) |
Sperm immobilizing antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (9 months) |
Please contact us in advance. | Immobilization method(Isojima method) |
(-) See the following criteria. |
Sperm immobilizing antibody (SI50)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (9 months) |
Please contact us in advance. | Immobilization method(Isojima method) | < 1.0 |
Lupus-anticoagulant
|
![]() plasma 1.0 |
PC5 ↓ A00 |
![]() |
![]() |
2-4 | APTT clotting time |
≦ 46.5 (seconds) |
Lupus-anticoagulant
|
![]() plasma 1.0 |
PC5 ↓ A00 |
![]() |
![]() (21 days) |
2-4 | Diluted Russell's viper venom time test | < 1.3 |
Lupus-anticoagulant
|
![]() plasma 1.0 |
PC5 ↓ A00 |
![]() |
![]() |
2-4 | Phospholipid neutralization method | ≦ 1.16 |
Anti-cardiolipin β2GP I complex antibody (anti-CL-β2 GP I antibody)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (1 month) |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 3.5 (U/mL) |
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 10 (U/mL) |
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
3-5 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 8 (U/mL) |
Anti-β2 glycoprotein Ⅰ antibody, IgG
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
<0.7 (U/mL) |
Anti-β2 glycoprotein Ⅰ antibody, IgM
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
≦17.5 (U/mL) |
Anti-cardiolipin antibody, IgG
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (7 days) |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
≦12.3 (U/mL) |
Anti-cardiolipin antibody, IgM
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (14 days) |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
≦20.8 (U/mL) |
Anti-platelet antibody
|
serum
0.4 |
S09 ↓ A00 |
![]() |
![]() |
3-6 | Mixed passive hemagglutination(MPHA) | Negative |
|
whole blood (with ACD-A)
7.5 |
PAC |
![]() |
![]() |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
≦ 46 (ng/107 cells) |
HIT antibody (Platelet factor 4-heparin complex antibody)
|
![]() plasma 0.5 |
PC2 ↓ A00 |
![]() |
![]() |
2-6 | Latex turbidimetry |
Negative: < 1.0 (U/mL) |
Serine proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 3.5 (U/mL) |
Myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-4 |
CLEIA Chemiluminescent enzyme immunoassay (CLEIA) |
< 3.5 (U/mL) |
Anti-LKM-1 antibody
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-8 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
< 17 See the following criteria. |
Immune complex (Monoclonal RF)
|
serum
0.2 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-8 |
EIA Enzyme immunoassay (EIA) |
< 4.2 (μg/mL) |
Anti-aquaporin 4 antibody
|
serum
0.4 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-8 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
Negative: < 3.0 (U/mL) |
Skin autoantibody, direct method
|
skin tissues
5×5×3mm |
VP1 |
![]() |
12-14 | Fluorescent antibody staining | ||
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ELISA Enzyme-linked immunosorbent assay (ELISA) |
≦ 3.0 (μg/mL) |
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Particle agglutination(PA) Particle agglutination (PA) |
Negative (< 100) (x) |
|
serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
Particle agglutination(PA) Particle agglutination (PA) |
Negative (< 100) (x) |
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ECLIA Electro chemiluminescence immunoassay (ECLIA) |
< 28 (IU/mL) |
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ECLIA Electro chemiluminescence immunoassay (ECLIA) |
< 2.0 (IU/L) |
|
serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ECLIA Electro chemiluminescence immunoassay (ECLIA) |
< 16 (IU/mL) |
|
serum
0.8 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
3-5 | Bioassay EIA |
≦ 120 (%) |
|
serum
0.9 |
S09 ↓ A00 |
![]() |
![]() |
7-13 | Indirect fluorescent antibody method | (-) |